BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23202613)

  • 21. Protocol: does sodium nitrite administration reduce ischaemia-reperfusion injury in patients presenting with acute ST segment elevation myocardial infarction? Nitrites in acute myocardial infarction (NIAMI).
    Siddiqi N; Bruce M; Neil CJ; Jagpal B; Maclennon G; Cotton SC; Papadopoulo SA; Bunce N; Lim P; Schwarz K; Singh S; Hildick-Smith D; Horowitz JD; Madhani M; Boon N; Kaski JC; Dawson D; Frenneaux MP
    J Transl Med; 2013 May; 11():116. PubMed ID: 23648219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mineralocorticoid receptor antagonist pretreatment to MINIMISE reperfusion injury after ST-elevation myocardial infarction (the MINIMISE STEMI Trial): rationale and study design.
    Bulluck H; Fröhlich GM; Mohdnazri S; Gamma RA; Davies JR; Clesham GJ; Sayer JW; Aggarwal RK; Tang KH; Kelly PA; Jagathesan R; Kabir A; Robinson NM; Sirker A; Mathur A; Blackman DJ; Ariti C; Krishnamurthy A; White SK; Meier P; Moon JC; Greenwood JP; Hausenloy DJ
    Clin Cardiol; 2015 May; 38(5):259-66. PubMed ID: 25990305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale and design of the MGuard for acute ST elevation reperfusion MASTER trial.
    Costa JR; Abizaid A; Dudek D; Silber S; Leon MB; Stone GW
    Catheter Cardiovasc Interv; 2013 Aug; 82(2):184-90. PubMed ID: 23008177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized controlled trial of TY-51924, a novel hydrophilic NHE inhibitor, in acute myocardial infarction.
    Kimura K; Nakao K; Shibata Y; Sone T; Takayama T; Fukuzawa S; Nakama Y; Hirayama H; Matsumoto N; Kosuge M; Hiro T; Sakuma H; Ishihara M; Asakura M; Hamada C; Kaneko A; Yokoi T; Hirayama A;
    J Cardiol; 2016 Apr; 67(4):307-13. PubMed ID: 26359711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection by atorvastatin pretreatment in patients undergoing primary percutaneous coronary intervention is associated with the lower levels of oxygen free radicals.
    Chen M; Li H; Wang Y
    J Cardiovasc Pharmacol; 2013 Sep; 62(3):320-4. PubMed ID: 23714773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myocardial reperfusion injury: looking beyond primary PCI.
    Fröhlich GM; Meier P; White SK; Yellon DM; Hausenloy DJ
    Eur Heart J; 2013 Jun; 34(23):1714-22. PubMed ID: 23536610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale and design of the Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients (the CIRCUS trial).
    Mewton N; Cung TT; Morel O; Cayla G; Bonnefoy-Cudraz E; Rioufol G; Angoulvant D; Guerin P; Elbaz M; Delarche N; Coste P; Vanzetto G; Metge M; Aupetit JF; Jouve B; Motreff P; Tron C; Labeque JN; Steg PG; Cottin Y; Range G; Clerc J; Coussement P; Prunier F; Moulin F; Roth O; Belle L; Dubois P; Barragan P; Gilard M; Piot C; Colin P; Morice MC; Monassier JP; Ider O; Dubois-Randé JL; Unterseeh T; Lebreton H; Beard T; Blanchard D; Grollier G; Malquarti V; Staat P; Sudre A; Hansson MJ; Elmer E; Boussaha I; Jossan C; Torner A; Claeys M; Garcia-Dorado D; Ovize M;
    Am Heart J; 2015 Jun; 169(6):758-766.e6. PubMed ID: 26027612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial.
    Atar D; Petzelbauer P; Schwitter J; Huber K; Rensing B; Kasprzak JD; Butter C; Grip L; Hansen PR; Süselbeck T; Clemmensen PM; Marin-Galiano M; Geudelin B; Buser PT;
    J Am Coll Cardiol; 2009 Feb; 53(8):720-9. PubMed ID: 19232907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.
    Woo JS; Kim W; Ha SJ; Kim JB; Kim SJ; Kim WS; Seon HJ; Kim KS
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2252-60. PubMed ID: 23868944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibiting the Inflammatory Injury After Myocardial Ischemia Reperfusion With Plasma-Derived Alpha-1 Antitrypsin: A Post Hoc Analysis of the VCU-α1RT Study.
    Abouzaki NA; Christopher S; Trankle C; Van Tassell BW; Carbone S; Mauro AG; Buckley L; Toldo S; Abbate A
    J Cardiovasc Pharmacol; 2018 Jun; 71(6):375-379. PubMed ID: 29634656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Intracoronary and Intravenous Melatonin on Myocardial Salvage Index in Patients with ST-Elevation Myocardial Infarction: a Randomized Placebo Controlled Trial.
    Ekeloef S; Halladin N; Fonnes S; Jensen SE; Zaremba T; Rosenberg J; Jonsson G; Aarøe J; Gasbjerg LS; Rosenkilde MM; Gögenur I
    J Cardiovasc Transl Res; 2017 Dec; 10(5-6):470-479. PubMed ID: 29027116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promising strategies to minimize reperfusion injury in STEMI.
    Bulluck H; Yellon RL; Yellon DM
    Minerva Cardioangiol; 2016 Jun; 64(3):284-94. PubMed ID: 26859232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apoptosis kinetics at reperfusion period in patients with acute ST-Segment Elevation Myocardial Infarction undergoing primary percutaneous coronary intervention and treated with thrombolytic therapy.
    Gultekin N; Bulut G; Kucukates E; Yildiz A; Kocas C; Bulut L
    J Pak Med Assoc; 2016 Jul; 66(7):808-14. PubMed ID: 27427127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial).
    Kandzari DE; Labinaz M; Cantor WJ; Madan M; Gallup DS; Hasselblad V; Joseph D; Allen A; Green C; Hidinger KG; Krucoff MW; Christenson RH; Harrington RA; Tcheng JE
    Am J Cardiol; 2003 Sep; 92(6):660-4. PubMed ID: 12972102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and rationale of low-dose erythropoietin in patients with ST-segment elevation myocardial infarction (EPO-AMI-II study): a randomized controlled clinical trial.
    Minamino T; Toba K; Higo S; Nakatani D; Hikoso S; Umegaki M; Yamamoto K; Sawa Y; Aizawa Y; Komuro I;
    Cardiovasc Drugs Ther; 2012 Oct; 26(5):409-16. PubMed ID: 22940818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.
    Gibson CM; Giugliano RP; Kloner RA; Bode C; Tendera M; Jánosi A; Merkely B; Godlewski J; Halaby R; Korjian S; Daaboul Y; Chakrabarti AK; Spielman K; Neal BJ; Weaver WD
    Eur Heart J; 2016 Apr; 37(16):1296-303. PubMed ID: 26586786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remote ischemic conditioning in ST-elevation myocardial infarction as adjuvant to primary angioplasty (RIC-STEMI): study protocol for a randomized controlled trial.
    Gaspar A; Pereira MÁ; Azevedo P; Lourenço A; Marques J; Leite-Moreira A
    Trials; 2015 Sep; 16():398. PubMed ID: 26350480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study.
    Husebye T; Eritsland J; Müller C; Sandvik L; Arnesen H; Seljeflot I; Mangschau A; Bjørnerheim R; Andersen GØ
    Eur J Heart Fail; 2013 May; 15(5):565-72. PubMed ID: 23288914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
    Ellis SG; Armstrong P; Betriu A; Brodie B; Herrmann H; Montalescot G; Neumann FJ; Smith JJ; Topol E;
    Am Heart J; 2004 Apr; 147(4):E16. PubMed ID: 15077099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated serum uric acid affects myocardial reperfusion and infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Mandurino-Mirizzi A; Crimi G; Raineri C; Pica S; Ruffinazzi M; Gianni U; Repetto A; Ferlini M; Marinoni B; Leonardi S; De Servi S; Oltrona Visconti L; De Ferrari GM; Ferrario M
    J Cardiovasc Med (Hagerstown); 2018 May; 19(5):240-246. PubMed ID: 29470249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.